Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin

Rudolph S Wagner1
David B Granet2
Steven J Lichtenstein3
Tiffany Jamison4
Joseph J Dajcs4
Robert D Gross5
Paul Cockrum4

1New Jersey Medical School, Newark, NJ, USA; 2Ratner Children’s Eye Center, University of California – San Diego, La Jolla, CA, USA; 3University of Illinois College of Medicine at Peoria, Peoria, Illinois, USA; 4Alcon Research, Ltd, Fort Worth, TX, USA; 5Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX, USA

Purpose: To compare the kinetics and speed of kill of Streptococcus pneumoniae and Haemophilus influenzae on exposure to three topical ophthalmic antibiotic solutions.

Materials and methods: Bacterial conjunctivitis isolates of S. pneumoniae and H. influenzae were exposed to 1:1000 dilutions of moxifloxacin 0.5%, tobramycin 0.3%, gentamicin 0.3%, and water (control). At 15, 30, 60, 120, and 180 minutes after exposure, aliquots were collected, cells were cultured, and viable cell counts were determined using standard microbiological methods.

Results: Moxifloxacin achieved 99.9% kill (3-log reduction) at approximately 2 hours for S. pneumoniae and at 15 minutes for H. influenzae. Tobramycin and gentamicin did not achieve 3-log reduction of S. pneumoniae during the 180-minute study period. An increase in bacterial growth was noted for these isolates. Gentamicin took more than 120 minutes to achieve the 3-log reduction of H. influenzae and tobramycin did not reach the 3-log reduction of this pathogen during the 180-minute study period.

Conclusion: Moxifloxacin killed S. pneumoniae and H. influenzae in vitro faster than tobramycin and gentamicin, suggesting its potential clinical benefit as a first-line treatment for bacterial conjunctivitis to minimize patient symptoms and to limit the contagiousness of the disease.

Keywords: kinetics of kill, bacterial conjunctivitis, in vitro, Streptococcus pneumoniae, Haemophilus influenzae, fluoroquinolones, aminoglycosides

Introduction

Conjunctivitis is a common disease, with considerable social and economic consequences due to disruption of usual patient and/or caregiver activities, such as lost days of school and/or work. Conjunctivitis can be caused by many ocular pathogens, but is mainly bacterial or viral in origin, with approximately 78% to 80% of cases being bacterial in origin.1 Bacterial conjunctivitis is particularly common in children, with Streptococcus pneumoniae and Haemophilus influenzae being the most common causative organisms.2 The disease is characterized by mucopurulent discharge, conjunctival injection, and morning matting of the lids.

The optimal treatment of bacterial conjunctivitis has been under debate for years. Opinions range from no treatment at all3 to treatment with new-generation fluoroquinolones.4 Although bacterial conjunctivitis is a self-limited disease lasting 7 to 14 days,5 initial therapy that offers a quick eradication of the causative pathogen is preferred.6 This rapid eradication minimizes contagiousness and allows for quick return to normal daily routines.6 In addition to bactericidal activity, an ophthalmic antibiotic should be safe, cost-effective, and have a favorable dosing regimen.
Aminoglycosides are a group of antibiotics derived from various species of Streptomyces that interfere with the function of bacterial ribosomes. From the early to late 1980s, prior to the use of ophthalmic fluoroquinolones, aminoglycosides were used frequently as a treatment for bacterial conjunctivitis. Included in this group of ocular antibiotics are tobramycin ophthalmic solution 0.3% (Tobrex®; Alcon Laboratories, Inc., Fort Worth, TX, USA) and gentamicin ophthalmic solution 0.3% (Genoptic®; Allergan, Inc., Irvine, CA, USA). The decreasing use of aminoglycosides is a result of the increasing resistance of Gram-positive organisms to this class of antibiotics and the increasing incidence of adverse ocular reactions. Since the 1990s, fluoroquinolones have gained widespread acceptance in the treatment of bacterial conjunctivitis because of the speed with which they eradicate bacteria. Fourth-generation fluoroquinolones provide the best coverage against Gram-positive organisms, including resistant strains, while maintaining coverage against Gram-negative organisms comparable to the earlier fluoroquinolones.

Despite the advantages of topical fluoroquinolones, clinicians have had some reservations regarding their use. Some have been concerned with speculative side effects, which may be attributed to side effects based on product labeling for systemic use. Some believe the use of topical fourth-generation fluoroquinolone antibiotics would lead to erosion of their clinical effectiveness to a greater degree than if the newer antibiotics were held in reserve and used only for patients who did not respond to initial therapy. Results from in vitro studies indicate that resistance to fourth-generation fluoroquinolones develops via multiple-step mutations. Therefore, fourth-generation fluoroquinolones maintain their clinical effectiveness because the probabilities of development of resistant strains in this class are much reduced. Additionally, clinicians may be less likely to prescribe newer antibiotics because of the perceived increase in cost, despite the more rapid kill, which can minimize the duration of symptoms and decrease contagion.

Moxifloxacin ophthalmic solution 0.5% (Vigamox®; Alcon Laboratories, Inc.) is a fourth-generation, 8-methoxy fluoroquinolone with a diazabicyclononyl ring at C7 position. The antibacterial action of moxifloxacin results from inhibition of the DNA gyrase and topoisomerase IV, whereas earlier-generation fluoroquinolones inhibited either DNA gyrase or topoisomerase IV. Moreover, the mechanism of action of the fourth-generation fluoroquinolones is different from that of macrorides, aminoglycosides, or tetracyclines, allowing moxifloxacin to be active against organisms that are resistant to these antibiotics.

The purpose of this study was to compare the time required in vitro for tobramycin and gentamicin (aminoglycosides) and moxifloxacin (fourth-generation fluoroquinolone) to kill S. pneumoniae and H. influenzae, the most common causative organisms of bacterial conjunctivitis in children.

Materials and methods
Bacterial isolates of S. pneumoniae and H. influenzae were isolated from patients who had bacterial conjunctivitis. Minimum inhibitory concentrations (MIC) of these two isolates for selected antibiotics were determined by broth micro dilution methods recommended by the National Committee for Clinical Laboratory Standards (NCCLS).

Kinetics of kill testing was used to compare the rates of kill of S. pneumoniae and H. influenzae by three ophthalmic products developed to topically treat bacterial conjunctivitis: moxifloxacin ophthalmic solution 0.5%, tobramycin ophthalmic solution 0.3%, and gentamicin ophthalmic solution 0.3%. Each product was tested at a 1:1000 dilution to approximate the concentrations remaining in the tear film 30 to 60 minutes after antibiotic instillation in the eye.

S. pneumoniae growing logarithmically at 35 °C in cation-adjusted Mueller-Hinton broth and H. influenzae growing logarithmically in Haemophilus Test Media broth were exposed to the diluted ophthalmic antibiotic products. At 15, 30, 60 minutes after exposure, aliquots of treated cells were withdrawn and serially diluted in cold phosphate-buffered saline with peptone. Aliquots containing S. pneumoniae (0.1 mL each) were spread onto trypticase soy agar plates supplemented with 5% sheep blood to determine the number of surviving colony-forming units per mL (CFU/mL). Likewise, 0.1 mL aliquots containing H. influenzae were spread onto chocolate agar plates. Plates were incubated at 35 °C for 24 hours and viable cell count was determined using standard methods.

Results
Kinetics of kill studies of moxifloxacin, tobramycin, and gentamicin were conducted with S. pneumoniae (MCC 40211) and H. influenzae (MCC 95018). The MIC susceptibility profiles of these isolates to selected antibiotics are presented in Table 1, which is similar to profiles previously reported in the literature. The kinetics of kill data for the two isolates are presented in Figures 1 and 3 as percent survivors from initial CFU/mL.

Streptococcus pneumoniae
Use of 1:1000 dilution of moxifloxacin 0.5% (5 µg/mL) for S. pneumoniae resulted in a 99% reduction in the percentage
of surviving CFU within 60 minutes of exposure and 99.9% reduction (3-log reduction) in the percentage of surviving CFU within 120 minutes of exposure. 1:1000 dilutions of tobramycin 0.3% (3 µg/mL) and gentamicin 0.3% (3 µg/mL) showed an increase in bacterial growth over the 180-minute study period (Figure 1). Plate photographs showed that moxifloxacin achieved almost complete eradication of bacterial growth 60 minutes after exposure, whereas tobramycin and gentamicin showed an increased bacterial growth at 60 minutes when compared with baseline (Time 0) (Figure 2).

**Haemophilus influenzae**

Use of 1:1000 dilution of moxifloxacin 0.5% (5 µg/mL) for *H. influenzae* resulted in a greater than 99.9% reduction in the percentage of surviving CFU within 15 minutes of exposure (Figure 3). 1:1000 dilutions of both tobramycin 0.3% (3 µg/mL) and gentamicin 0.3% (3 µg/mL) showed an increase in bacterial growth during the first 60 minutes of the study period. Gentamicin achieved a 3-log reduction of viable cell counts within 180 minutes of exposure, whereas tobramycin did not achieve the 3-log reduction during the 180-minute study period. Plate photographs showed that moxifloxacin achieved almost complete eradication of bacterial growth within 15 minutes after exposure, whereas tobramycin and gentamicin showed an increased bacterial growth at 60 minutes when compared with baseline (Time 0) (Figure 4).

### Table 1 Minimum inhibitory concentration (µg/mL) of *Streptococcus pneumoniae* and *Haemophilus influenzae* isolates to selected antibiotics

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th><em>S. pneumoniae</em> (MCC 40211)</th>
<th><em>H. influenzae</em> (MCC 95018)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moxifloxacin</td>
<td>0.125</td>
<td>0.015</td>
</tr>
<tr>
<td>Tobramycin</td>
<td>32</td>
<td>2</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>16</td>
<td>2</td>
</tr>
</tbody>
</table>

![Figure 1](https://www.dovepress.com/clinical-ophthalmology-2010-4.png)

**Figure 1** Percent survivors of *Streptococcus pneumoniae* (MCC 40211) as a function of time.

**Figure 2** Photographs of *Streptococcus pneumoniae* (MCC 40211) grown on blood agar plates after exposure to 1:1000 dilutions of moxifloxacin (5 µg/mL), tobramycin (3 µg/mL), gentamicin (3 µg/mL), and water control.

**Discussion**

The most appropriate antibiotic therapy for patients with contagious bacterial conjunctivitis should eliminate infection quickly to minimize both the signs and symptoms and the spread of the disease. The antibiotic also should be safe, well-tolerated, have a convenient dosing regimen to encourage adherence, and be cost-effective.16

The economic burden of bacterial conjunctivitis is substantial and involves both direct and indirect costs. The direct costs of treating patients with bacterial conjunctivitis in the United States was estimated at approximately $765 million in 2005.17 Currently, there is no consensus among state health officials regarding students’ absence(s) due to bacterial conjunctivitis. The issue of whether or not to require a child’s absence from school if the student is found to have bacterial conjunctivitis has to do with more than just the likelihood that the child will
Infect others. Students’ absenteeism affects their academic performance, the schools’ State and Federal funding, and employers’ productivity due to lost work time by parents or caregivers. It is estimated, depending on the state and the school district, that schools lose approximately $32 to $42 of State and/or Federal funding per student per missed school day (excused or unexcused). The 2009 United States Department of Labor’s Wage and Hour Division (WHD) federal minimum wage laws indicate that a minimum-wage earning parent or caregiver who loses one working day to care for a child with bacterial conjunctivitis loses between $41.20 and $68.4 in wages, depending on the minimum wage set by the state. Therefore, the cost-effectiveness of an antibiotic, not simply the unit price, is an important measure that allows clinicians to choose the ideal antibiotics.

This current study investigated the kinetics of kill of moxifloxacin 0.5%, a commonly prescribed fourth-generation fluoroquinolone antibiotic, and two aminoglycoside antibiotics (tobramycin and gentamicin) on S. pneumoniae and H. influenzae, the two most commonly isolated organisms in bacterial conjunctivitis in children. The antibiotics were diluted 1:1000 to represent the concentration of the antibiotic in the eye 30 to 60 minutes after instillation. Moxifloxacin demonstrated a more rapid bacterial kill than either one of the aminoglycosides, achieving 99.9% kill (bactericidal effect) of S. pneumoniae within 120 minutes of exposure and 99.9% kill of H. influenzae within 15 minutes of exposure. Aminoglycosides did not kill S. pneumoniae during the 180-minute study period, and their speed of bacterial kill of H. influenzae was much slower than that of moxifloxacin. Similar kinetics of kill studies conducted separately against H. influenzae with moxifloxacin ophthalmic solution 0.5% and fusithalmic acid 1.0% demonstrated similar results (data not shown). Moxifloxacin eradicated H. influenzae within 15 minutes while fusithalmic acid was unable to kill the bacteria during the 60-minute study period. Collectively, the findings from these in vitro studies suggest that moxifloxacin might eradicate rapidly S. pneumoniae and H. influenzae in patients with bacterial conjunctivitis, possibly translating into faster symptom resolution and a reduced chance of disease transmission. This may lead to a decrease in the number of days needed to achieve resolution of symptoms and the economic benefits of a reduction in the rate of school absenteeism by affected children and in the loss of work days by parents and/or caregivers.

There are some limitations to in vitro kinetics of kill studies. First, these studies report results based on a constant concentration of active product rather than the changing concentrations that are expected in the eye after instillation of the antibiotic. Second, kinetics of kill studies are conducted after a single exposure to antibiotics; therefore, the application of this model for bacteria exposed to multiple daily doses of antibiotic is unknown. For these reasons, results of in vitro kinetics of kill

![Graph showing the kinetics of kill of moxifloxacin, tobramycin, and gentamicin against H. influenzae](image)

**Figure 3** Percent survivors of Haemophilus influenzae (MCC 95018) as a function of time.
studies should be confirmed in clinical studies, although few comparative clinical studies are available. Granet et al. demonstrated that moxifloxacin 0.5% dosed 3 times daily cured bacterial conjunctivitis faster and more effectively than polymyxin B sulfate/trimethoprim dosed 4 times daily, with *H. influenzae* being the most commonly isolated organism in that study.

**Conclusion**

Kinetics of kill studies with moxifloxacin ophthalmic solution 0.5% support a greater speed of kill against *S. pneumoniae* and *H. influenzae* than with the aminoglycosides, tobramycin ophthalmic solution 0.3% and gentamicin ophthalmic solution 0.3%. Rapid bacterial eradication of pathogenic bacteria is a favorable characteristic of an antibiotic because it minimizes the spread of the disease and provides quicker clinical resolution, of which have tremendous socioeconomic impact on children and their families.

**Acknowledgment**

The study was conducted at Alcon Research, Ltd., Fort Worth, TX, USA.

Editorial assistance in the preparation of this manuscript was provided by Heba Costandy, MD, MS, of H H Consulting, Inc. Support for this assistance was provided by Alcon Research, Ltd.

**Disclosures**

Jamison T, Dajes JJ, Gross RD, and Cockrum P are employees of Alcon Research, Ltd. and Drs Wagner, Granet, and Lichtenstein are consultants for Alcon Research, Ltd. None of the authors has any proprietary or financial interest in moxifloxacin, tobramycin or gentamicin.

**References**